Lilly shares close at $1,115.70 with a market value around $1 trillion

Eli Lilly shares closed at $1,115.70 on September 11, 2026, a level that keeps the company's market capitalization near $1 trillion ^[3]. The stock has climbed about 51% over the past twelve months, though one source puts the one-year gain at 50.72% and another at 48.46%, a small discrepancy in the exact figure ^[2][3]. Shares are also down roughly 9% from their 52-week high of $1,292.65, which was reached earlier this year ^[2][3].

The rally has been driven largely by Lilly's GLP-1 medicines. Incretin drugs, including Mounjaro and Zepbound, made up 65% of Lilly's revenue for the first six months of 2026 ^[3]. In the second quarter of 2026, total company revenue reached $22.974 billion, up 47.67% from a year earlier, and earnings per share of $8.38 beat Wall Street estimates by 27.27% ^[2]. Mounjaro alone brought in $9.94 billion in the quarter, a 91% increase from the same period last year, and management raised its full-year revenue guidance to a range of $85 billion to $87 billion ^[2].

But the numbers also show a tension investors are watching closely. Realized prices, meaning what Lilly actually collects per prescription after discounts and rebates, fell 13% in the second quarter ^[2]. That decline was offset by a 60% increase in sales volume, meaning far more prescriptions were filled even as the average price per prescription dropped ^[2]. The incretin franchise, which includes Mounjaro, Zepbound, and the oral drug Foundayo, generated about $14.87 billion of the quarter's total revenue ^[2].

Foundayo, an oral GLP-1 medicine that Lilly says has no food or water restrictions, launched in the U.S. during the second quarter of 2026 and had expanded to 36,000 prescribers as of early September ^[2][3]. Lilly also took $2.78 billion in acquired in-process research and development charges in the second quarter, tied to a string of biotech acquisitions the company has made this year, including deals for Orna, Kelonia, Ajax, and Centessa ^[2][3].

Why it matters for patients

The volume-versus-price pattern in Lilly's results is a snapshot of what's happening in pharmacies. More people are filling prescriptions for Mounjaro, Zepbound, and now Foundayo, but the company is collecting less money per prescription, likely reflecting rebates, competition, and payer negotiations ^[2]. For patients, this dynamic connects to a separate development: the Medicare GLP-1 Bridge Program, which as of July 2026 opened coverage for Wegovy at $50 a month for about 20 million eligible Americans ^[2]. Whether falling realized prices translate into lower costs for patients broadly, or mainly reflect deals with insurers and government programs, is not detailed in these sources.

The rapid expansion of Foundayo's prescriber base, now 36,000 doctors, suggests wider access to an oral option that doesn't require the food and water timing restrictions of some other oral GLP-1 drugs ^[2]. Investors are treating that expansion as a growth signal, but the sources do not report how many patients have actually started the drug or what out-of-pocket costs look like for most people.

What happens next

Lilly's next earnings report is expected around October 29, 2026 ^[3]. Investors and analysts are also watching for a possible Biologics License Application submission for retatrutide, a triple-agonist drug Lilly has in Phase 3 trials, which the company has said it plans to file in the first quarter of 2027 ^[2]. Whether pricing pressure continues to intensify, or volume growth keeps outpacing price declines, will likely shape how affordable these drugs become and how widely insurers cover them in the coming quarters ^[2].